DURECT Q1 2024 Earnings Preview
DURECT (NASDAQ:DRRX) is scheduled to announce Q1 earnings results on Monday, May 13th, after market close. The consensus EPS Estimate is -$0.22 (+57.7% Y/Y) and the consensus Revenue Estimate is ...
Seeking Alpha4d
CRL Charles River Laboratories International, Inc.
Charles River Laboratories International, Inc. provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and ...
ahajournals.org9h
Orphan G Protein–Coupled Receptor GPRC5B Controls Smooth Muscle Contractility and Differentiation by Inhibiting Prostacyclin Receptor Signaling
Department of Pharmacology (J.C., R.C., R.L., H.K., W.Z., S.T., S.O., N.W.), Max Planck Institute for Heart and Lung Research, Bad Nauheim, Germany. Department of ...
ahajournals.org3d
Angiotensin-Converting Enzyme Inhibitors
From the Hypertension and Vascular Research Division (H.P., O.A.C., N.V., T.-D.L., A.M., N.-E.R.) and the Biostatistics and Research Epidemiology Division (E.L.P ...